Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir

John N Mafi; Sitaram Vangala; Moira K Kapral; Peter E Wu; Manying Cui; Artem Romanov; Katherine L Kahn

doi:10.1001/jama.2024.28099

Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir

JAMA. 2025 Feb 20;333(13):1172-1175. doi: 10.1001/jama.2024.28099. Online ahead of print.

Authors

John N Mafi^{1

2}, Sitaram Vangala¹, Moira K Kapral^{3

4}, Peter E Wu^{3

5}, Manying Cui¹, Artem Romanov¹, Katherine L Kahn^{1

2}

Affiliations

¹ Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, California.
² RAND Corporation, Santa Monica, California.
³ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ ICES, Toronto, Ontario, Canada.
⁵ Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

PMID: 39976986
PMCID: PMC11843459 (available on 2025-08-20)
DOI: 10.1001/jama.2024.28099

No abstract available

Plain language summary

This study compares hospitalization and mortality outcomes in vaccinated older adults with vs without restricted access to nirmatrelvir-ritonavir in Ontario.